- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 741
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anorexia, Cachexia, Weight Loss
- Interventions
- Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo
- Drug
- Lead sponsor
- Par Pharmaceutical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Anaheim, California • Flat Rock, North Carolina • High Point, North Carolina + 1 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Placebo, Risdiplam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California • New York, New York
- Conditions
- Post Operative Pain
- Interventions
- Methadone Hydrochloride
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Gastrointestinal Health
- Interventions
- Dietary fiber
- Other
- Lead sponsor
- Ingredion Incorporated
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Glen Ellyn, Illinois
- Conditions
- Hereditary Periodic Fevers
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Obesity
- Interventions
- BMF-650
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Obesity or Overweight
- Interventions
- AZD9550, AZD6234, Placebo comparator
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 29
- States / cities
- Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
- Conditions
- Tourette Syndrome in Children, Tourette Syndrome in Adolescence
- Interventions
- T92, Placebo
- Dietary Supplement
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Psychological Effects of Study Drug
- Interventions
- Lactose (inactive placebo), midomafetamine HCl
- Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 3
- States / cities
- Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
- Conditions
- Anthracycline Related Cardiotoxicity in Breast Cancer
- Interventions
- sulforaphane, Placebo Oral Tablet
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Bipolar Disorder, Weight Gain
- Interventions
- Topiramate, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Ibodutant 10 mg, Placebo
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- Pertzye
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pediatric Crohn's Disease
- Interventions
- Methotrexate, Sugar pill (placebo)
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
- Conditions
- Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2
- Interventions
- alglucosidase alfa, Placebo
- Biological · Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
- Conditions
- Cachexia
- Interventions
- BYM338 active drug, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
- Conditions
- Hepatic Steatosis
- Interventions
- Cholic Acid
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure, Chronic Heart Failure
- Interventions
- Heartfelt Device installed, Standard care, Heartfelt-guided care, Questionnaires
- Device · Other
- Lead sponsor
- Heartfelt Technologies
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Hackensack, New Jersey • Bala-Cynwyd, Pennsylvania
- Conditions
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
- Interventions
- Placebo, Vanquix Auto-Injector (Diazepam Injection)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 86
- States / cities
- Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
- Conditions
- Nasal Polyps, Chronic Rhinosinusitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Rancho Cordova, California + 13 more
- Conditions
- Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
- Interventions
- MitoQ, Placebo
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Belmont, Massachusetts